Eliem Therapeutics (NASDAQ:ELYM) Stock Price Crosses Above Two Hundred Day Moving Average – Should You Sell?

Eliem Therapeutics, Inc. (NASDAQ:ELYM – Get Free Report) crossed above its 200-day moving average during trading on Tuesday. The stock has a 200-day moving average of $10.48 and traded as high as $11.54. Eliem Therapeutics shares last traded at $11.01, with a volume of 1,783,991 shares.

Eliem Therapeutics Stock Up 4.3%

The company has a market cap of $364.46 million, a price-to-earnings ratio of -23.11 and a beta of -0.39. The company’s 50-day moving average is $11.78 and its 200 day moving average is $10.51.

Eliem Therapeutics Company Profile

(Get Free Report)

Eliem Therapeutics was a clinical-stage biopharmaceutical company focused on developing treatments for neurological and psychiatric disorders. Its research centered on therapies that modulate neuronal activity, with the goal of addressing conditions with significant unmet medical needs. One of its investigational programs was ETX-155, an oral compound designed to act on GABA-A receptors. The company studied the treatment for major depressive disorder and epilepsy; it was investigational and had not been established as a treatment for either condition.

Further Reading

Receive News & Ratings for Eliem Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eliem Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.